Methods and compositions using Kloto-FGF23 fusion polypeptides
AssigneeNovartis AG
InventorsDavid Glass, Shou-Ih Hu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.
Claims17
A functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide comprises the sequence of SEQ ID NO:
- 51.
A nucleic acid comprising a sequence that encodes a functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide comprises the sequence of SEQ ID NO:
- 51.
A method for activating Egr-1 in an individual, comprising the step of:
- administering to the individual a therapeutically effective dose of a pharmaceutical composition comprising a functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide comprises the sequence of SEQ ID NO:
- 51.
A functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide consists of the sequence of SEQ ID NO:
- 51.
A nucleic acid comprising a sequence that encodes a functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide consists of the sequence of SEQ ID NO:
- 51.
Dependencies are inferred from the claim text.